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Abstract: AIMS To compare the safety and efficacy of edoxaban combined with P2Y12 inhibition follow-
ing percutaneous coronary intervention (PCI) in patients with atrial fibrillation (AF) presenting with an
acute coronary syndrome (ACS) or chronic coronary syndrome (CCS). METHODS AND RESULTS In
this pre-specified sub-analysis of the ENTRUST-AF PCI trial, participants were randomly assigned 1:1
to edoxaban- or vitamin K antagonist (VKA)-based strategy and randomization was stratified by ACS
(edoxaban n = 388, VKA n = 389) vs. CCS (edoxaban n = 363, VKA = 366). Participants received
edoxaban 60 mg once-daily plus a P2Y12 inhibitor for 12 months, or VKA combined with a P2Y12
inhibitor and aspirin 100 mg (for 1-12 months). The primary bleeding endpoint at 12 months occurred in
59 (15.2%) vs. 79 (20.3%) ACS patients [hazard ratio (HR): 0.73, 95% confidence interval (CI): 0.59-1.02,
P = 0.063], and in 69 (19.0%) vs. 73 (19.9%) CCS patients (HR: 0.94, 95%CI: 0.68-1.31, P = 0.708)
with edoxaban- and VKA-based therapy, respectively [P for interaction (P-int) = 0.2741]. The main
secondary endpoint (composite of CV death, myocardial infarction, stroke, systemic embolic events, or
definite stent thrombosis) in ACS patients was 33 (8.5%) vs. 28 (7.2%) (HR: 1.16, 95%CI: 0.70-1.92),
compared with 16 (4.4%) vs. 18 (4.9%) (HR: 0.91, 95%CI: 0.47-1.78) CCS patients with edoxaban and
VKA-based therapy, respectively (P-int = 0.5573). CONCLUSIONS In patients with AF who underwent
PCI, the edoxaban-based regimen, as compared with VKA-based regimen, provides consistent safety and
similar efficacy for ischaemic events in patients with AF regardless of their clinical presentation.
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Aims To compare the safety and efficacy of edoxaban combined with P2Y12 inhibition following percutaneous coronary
intervention (PCI) in patients with atrial fibrillation (AF) presenting with an acute coronary syndrome (ACS) or




In this pre-specified sub-analysis of the ENTRUST-AF PCI trial, participants were randomly assigned 1:1 to edoxa-
ban- or vitamin K antagonist (VKA)-based strategy and randomization was stratified by ACS (edoxaban n=388,
VKA n=389) vs. CCS (edoxaban n=363, VKA= 366). Participants received edoxaban 60mg once-daily plus a
P2Y12 inhibitor for 12months, or VKA combined with a P2Y12 inhibitor and aspirin 100mg (for 1–12months). The
primary bleeding endpoint at 12months occurred in 59 (15.2%) vs. 79 (20.3%) ACS patients [hazard ratio (HR):
0.73, 95% confidence interval (CI): 0.59–1.02, P=0.063], and in 69 (19.0%) vs. 73 (19.9%) CCS patients (HR: 0.94,
95%CI: 0.68–1.31, P=0.708) with edoxaban- and VKA-based therapy, respectively [P for interaction (P-int) =
0.2741]. The main secondary endpoint (composite of CV death, myocardial infarction, stroke, systemic embolic
events, or definite stent thrombosis) in ACS patients was 33 (8.5%) vs. 28 (7.2%) (HR: 1.16, 95%CI: 0.70–1.92),
compared with 16 (4.4%) vs. 18 (4.9%) (HR: 0.91, 95%CI: 0.47–1.78) CCS patients with edoxaban and VKA-based
therapy, respectively (P-int = 0.5573).
...................................................................................................................................................................................................
Conclusions In patients with AF who underwent PCI, the edoxaban-based regimen, as compared with VKA-based regimen, pro-
vides consistent safety and similar efficacy for ischaemic events in patients with AF regardless of their clinical
presentation.
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Introduction
Anticoagulation with currently marketed non-vitamin K antagonist
oral anticoagulants (NOACs), in patients with atrial fibrillation (AF)
who develop an acute coronary syndrome (ACS) and/or undergo
percutaneous coronary intervention (PCI) has been studied in four
large controlled randomized trials.1–4
The ENTRUST-AF PCI trial, the most recent among the four
NOAC trials, included patients with AF and either ACS or chronic
coronary syndrome (CCS), and demonstrated similar rates of bleed-
ing and ischaemic events with an antithrombotic regimen consisting
of edoxaban and a P2Y12 inhibitor without aspirin compared with a
regimen that included a vitamin K antagonist (VKA) in combination
with a P2Y12 inhibitor and aspirin (for 1–12months).
4 Randomization
was stratified according to clinical presentation (ACS vs. CCS).4,5
The comparative safety and efficacy of combination regimens of
antiplatelets and anticoagulants may differ among patients with AF
according to their clinical presentation. Therefore, we pre-specified
to assess the consistency of the treatment effects among patients




The details of the ENTRUST-AF PCI trial (ClinicalTrials.gov,
NCT02866175) design and results have been reported.4,5 In brief, the
ENTRUST-AF PCI trial was an international, randomized, open-label
phase 3b trial with masked outcome assessment in AF patients under-
going PCI and taking a P2Y12 inhibitor who were assigned to edoxaban or
VKA and aspirin 100mg once-daily.
The trial was conducted in compliance with the Declaration of
Helsinki and Good Clinical Practice, as defined by the International
Conference onHarmonization. The study protocol was approved by eth-
ics committees or institutional review boards at participating sites;
patients provided written informed consent prior to inclusion in the
study.
Randomization and treatment
Once written informed consent was obtained, randomization took place
between 4 h to 5 days after successful PCI and before hospital discharge.
If a staged PCI was planned, consent and randomization took place after
completion of the last stage.
Randomization was performed with the use of a central, 24-h, inter-
active web-response system and stratified according to geographic loca-
tion (country), clinical presentation (ACS or CCS), and fulfilment of
edoxaban dose-reduction criteria. Stratification by geographic region was
opted to ensure balance across potential local differences in treatment
practices.
The edoxaban-based regimen consisted of treatment with edoxaban
60/30mg once-daily and clopidogrel bisulphate 75mg once-daily [or in
the presence of a documented clinical need, prasugrel (5 or 10mg once-
daily) or ticagrelor (90mg twice-daily)] for 12months. A reduced dose of
edoxaban 30mg once-daily was used in patients if any of the following
characteristics were present at the time of randomization or during the
study period: moderate or severe renal impairment (calculated creatinine
clearance 15–50mL/min), low body weight of <_60kg (132 lbs), or con-
current use of certain potent P-glycoprotein inhibitors.
The VKA-based regimen was dose-adjusted to achieve an international
normalized ratio (INR) between 2.0 and 3.0 inclusive, in combination
with clopidogrel bisulphate 75mg once-daily [or in the presence of a
documented clinical need, prasugrel (5 or 10mg once-daily) or ticagrelor
(90mg twice-daily)] for 12months and aspirin (100mg once-daily) for a
minimum of 1month and up to 12 months’ duration at the investigator’s
discretion. In the control group, INR management was according to the
standard of care and performed by the Investigator, the patient’s primary
care physician, or other private physician, at a specialized anticoagulation
clinic or by patient self-monitoring. The duration of the aspirin treatment
in the VKA-based regimen was pre-declared by the investigator prior to
randomization guided by the clinical presentation (ACS or CCS) and
based upon the CHA2DS2-VASc and HAS-BLED scores. The investigator
followed the applicable regional clinical guidelines.5
The assigned regimen was implemented after randomization without
any undue delay and the randomized regimens (edoxaban-based or VKA-
based) and clopidogrel (or other P2Y12 inhibitor) were continued for
12months, when the scheduled end-of-treatment was reached. The use
of gastric protection drugs (such as pantoprazole) was recommended.
Study visits were performed at 1, 3, 6, 9, and 12months after random-
ization, and telephone assessments at 2, 4, 5, 7, 8, 10, and 11months after
randomization. INR monitoring was in accordance with routine care at
the respective centre, but the level of INR control was collected and cen-
trally monitored. To assure study drug compliance and maintain INR in
target range, at least monthly contact was scheduled in both the edoxa-
ban and VKA treatment groups.
Outcomes
The primary outcome was the first occurrence of International Society
on Thrombosis and Haemostasis (ISTH) major or clinically relevant non-
major (CRNM) bleeding. ISTHmajor bleeding is defined as clinically overt
bleeding with a haemoglobin drop of >_2 g/dL or transfusion of >_2 units of
packed red cells, or bleeding occurring at a critical site or resulting in
death. CRNM bleeding is defined as any overt bleeding that did not meet
the criteria for major bleeding and met >_1 of the following criteria:
requires hospitalization; requires a physician-guided medical or surgical
intervention to treat the bleeding, or results in unscheduled contact with
a physician (visit or telephone call); results in pain or impairment of daily
activities; or results in a physician-guided change in antithrombotic
therapy.6
Secondary efficacy outcomes included the composite of cardiovascular
death (CVD), myocardial infarction (MI), stroke (modified Valve
Academic Research Consortium-2 definition),7 systemic embolic event
(SEE), or definite stent thrombosis [according to the academic research



















































































































































consortium (ARC) criteria]; and net clinical benefit, defined as the com-
posite of CVD, stroke, SEE, spontaneous MI, definite stent thrombosis
(according to the ARC criteria),8 and ISTH-defined major bleeding.
Other outcomes included ISTH major bleeding, CRNM and individual
components of the composite outcomes. All outcomes were adjudicated
according to standard definitions by an independent committee blinded
to treatment assignment.
Statistical analysis
Baseline characteristics were summarized for each of the two subgroups
(ACS and CCS) by treatment allocation (edoxaban-based treatment or
VKA-based treatment). Categorical variables were compared with the
use of the chi-square test or Fisher’s exact test. Continuous variables
were compared with the use of Student’s t-test or the Wilcoxon’s rank-
sum test for non-normally distributed data.
For each of the outcomes, the proportion of patients with at least one
event was calculated and summarized.
All analyses were performed according to the intention-to-treat (ITT)
principle, including all patients in the analysis according to the clinical
presentation, taking into account all outcome events irrespective of
whether the randomized treatment was taken or not; and repeated, for
sensitivity reasons, for the on-treatment population. All events were
counted from randomization through the 12-month visit or the last day
of known outcome status, whichever came first.
We analysed primary and secondary endpoints separately for ACS
and CCS patients, based on time to occurrence of first event using a Cox
proportional hazard model including treatment group, and the two strati-
fication factors: geographic region and requirement for dose adjustment
to derive hazard ratios (HR) with 95% confidence intervals (CIs). In add-
ition, we used an extended Cox model adding clinical presentation and
the interaction term between treatment and clinical presentation to per-
form treatment-by-subgroup interaction tests. There was no pre-
specified hierarchical testing of endpoints.
The differences between anticoagulant treatments within each of the
subgroups were tested and characterized by HRs and corresponding
95% CIs from a Cox proportional hazards model.
To evaluate whether the low INR rates shortly after randomization
led to the apparent violation of the proportional hazards assumption, we
performed a post hoc landmark analysis with a landmark in the first
Figure 1 Study outcomes, Intent-to-Treat analysis (N=1506) separately by clinical presentation (ACS, chronic coronary syndrome). (A) Safety
outcomes; (B) Efficacy outcomes; and (C) Net clinical benefit. ACS, acute coronary syndrome; ARC, academic research consortium; CCS, chronic
coronary syndrome; CI, confidence interval; CV, cardiovascular; HR, hazard ratio; ICH, intracranial haemorrhage; ISTH, International Society on
Thrombosis and Haemostasis; ITT, intent-to-treat; MI, myocardial infarction; NA, not available; SEE, systemic embolic event; VKA, vitamin K antagon-
ist. P-value of interaction results are based on a Cox model with treatment group, the three stratification factors: geographic region, requirement for
dose adjustment and clinical presentation, and the interaction term between clinical presentation and treatment.








































































































































14days. The 14 days’ time frame was selected based on the INR distribu-
tion over time and visual inspection of the Kaplan–Meier (KM) curve.
The primary statistical analysis was performed by statisticians con-
tracted by a contract research organization (Chiltern) and checked for
consistency by a second statistician employed by the sponsor. All statis-
tical analyses were performed in SAS (version 94).
Results
A total of 1506 patients were randomized from 186 sites in 18 coun-
tries (Supplementary material online, Figure S1). Among them, 51.6%
(n=777) presented with an ACS and 48.4% (n=729) with CCS
(Supplementary material online, Table S1). A total of 320 (21.1%)
patients were documented with ST-elevation myocardial infarction
(STEMI) and 265 (17.6%) with non-STEMI (NSTEMI). Acute coronary
syndrome patients (59.3% and 58.1% in the edoxaban and VKA treat-
ment groups, respectively) had more frequently presented with par-
oxysmal AF than CCS patients (47.4% and 36.2%, respectively) who
had in turn a higher incidence of previous cardiovascular events or
congestive heart failure (Supplementary material online, Table S1).
The median (Q1; Q3) CHA2DS2-VASc scores for the ACS and CCS
groups were identical at 4.0 (3.0; 5.0), whereas the mean (SD) scores
were 3.85 (1.60) and 3.86 (1.57), respectively. The median HAS-
BLED (Q1; Q3) scores were identical at 3.0 (2.0; 3.0), and the mean
(SD) scores were 2.82 (0.83) among ACS and 2.91 (0.80) among
CCS patients.
The baseline characteristics for the comparison of edoxaban with
VKA treatment groups were well balanced across subgroups
(Supplementary material online, Table S1). Among patients assigned
Figure 2 The primary, the main secondary, and the net clinical benefit outcomes comparing edoxaban with vitamin K antagonist across acute cor-
onary syndrome and chronic coronary syndrome groups over 12months, mITT analysis set, on-treatment analysis. (A) The primary outcome of
major or CRNM bleeding [ISTH] by clinical presentation (acute coronary syndrome or chronic coronary syndrome) over 12 months. (B) The sec-
ondary efficacy outcome [composite of cardiovascular death, stroke (VARC-2), systemic embolic event, myocardial infarction or definite stent
thrombosis] by clinical presentation (acute coronary syndrome or chronic coronary syndrome) over 12 months. (C) The net clinical benefit defined
as the composite of CV death, stroke (VARC-2), systemic embolic event, myocardial infarction, definite stent thrombosis and major bleeding (ISTH)
by clinical presentation (acute coronary syndrome or chronic coronary syndrome) over 12 months. ACS, acute coronary syndrome; CCS, chronic
coronary syndrome; CI, confidence interval; CV, cardiovascular; HR, hazard ratio; ISTH, International Society on Thrombosis and Haemostasis; MI,
myocardial infarction; MITT, modified intention-to-treat; SEE, systemic embolic event; VARC, valve academic research consortium; VKA, vitamin K
antagonist.

















































































































































































































to the VKA regimen, triple-antithrombotic therapy was taken for a
median of 145.2 days (IQR 30–266) in ACS patients and 108.4 days
(IQR 29–161) in CCS patients. The median time in therapeutic range
(INR 2.0–3.0) was 62.4% (IQR 45.5–74.5) and 64.4% (IQR 46.9–76.4)
respectively. Based on the on-treatment analysis set, 71 (18.4%) of
385 ACS patients vs. 59 (16.3%) of 361 CCS patients prematurely
discontinued the edoxaban-based regimen and 83 (21.8%) of 380
ACS patients vs. 77 (21.4%) of 360 CCS patients prematurely discon-
tinued the VKA regimen. Adherence to the intended aspirin duration
is reported in Supplementary material online, Table S2.
Safety and efficacy outcomes comparing
edoxaban with VKA across subgroups at
12months
Among patients treated with edoxaban or VKA, the primary end-
point of ISTH major or CRNM bleeding at 12months occurred in 59
(15.2%) vs. 79 (20.3%) patients, respectively, in the ACS group (HR
0.73, 95% CI 0.59–1.02, P=0.063), and in 69 (19.0%) vs. 73 (19.9%)
patients, respectively, in the CCS group (HR 0.94, 95% CI 0.68–1.31,
P=0.708) in CCS patients, P for interaction (P-int) = 0.2741
(Figure 1A and Supplementary material online, Table S3). Figure 2A–C
summarizes the primary, the main secondary, and the net clinical
benefit outcomes comparing edoxaban with VKA across both
subgroups.
Rates of bleeding according to ISTH, Thrombolysis in Myocardial
Infarction (TIMI), and bleeding Academic Research Consortium
(BARC) definitions were consistent (Supplementary material online,
Table S4).
The main secondary efficacy endpoint was similar when comparing
edoxaban vs. VKA in both subgroups and occurred in 33 (8.5%) vs.
28 (7.2%) ACS patients [HR 1.16 (0.70–1.92), P: 0.575], and in 16
(4.4%) vs. 18 (4.9%) CCS patients [HR 0.91 (0.47–1.78), P: 0.783]
with no statistical evidence for treatment-by-subgroup interaction
(P-int: 0.5573) (Figure 1B and Supplementary material online,
Table S3).
The net clinical benefit outcomes occurred in 46 (11.9%) vs. 47
(12.1%) ACS patients [HR 0.97 (0.64–1.44), P: 0.867], and 36 (9.9%)
vs. 36 (9.8%) CCS patients [HR 1.01 (0.64–1.62), P: 0.957], with no
statistical evidence for interaction (P-int: 0.8768) (Figure 1C and
Supplementary material online, Table S3).
Risk estimates for the comparison of both groups regarding
Academic Research Consortium (ARC)-defined definite stent throm-
bosis were imprecise due to the low number of events. However,
tests for treatment-by-subgroup interaction were not significant with
respect to MI (P-int = 0.409), stroke (P-int = 0.195), and definite stent
thrombosis (P-int = 0.518). Most stent thrombosis in the edoxaban-
treated patients occurred early after randomization (Table 1). The
type of MI and timing, by clinical presentation are shown in Table 2.
All-cause death occurred in 32 (8.20%) vs. 24 (6.20%) ACS
patients [HR 1.30 (0.77–2.21), P: 0.328], and 14 (3.90%) vs. 13
(3.60%) CCS patients [HR 1.12 (0.53–2.39), P: 0.770], with no statis-
tical evidence for interaction (P-int: 0.7074) (Figure 1B and
Supplementary material online, Table S5).
Post hoc landmark analysis
The landmark analyses are presented in Figure 3A and B. Analyses up
to 14 days, and from 15days to 1 year did not show any significant
.................................................................................................
Table 1 Occurrence of probable and definite stent
thrombosis after randomization
N (n) Edoxaban VKA Total
Definite ST ACS 5 (4) 5 (0) 10 (4)
CCS 3 (2) 1 (0) 4 (2)
total 8 (6) 6 (0) 14 (6)
Probable ST ACS 4 (4) 4 (2) 8 (6)
CCS 1 (1) 0 (0) 1 (1)
Total 5 (5) 4 (2) 9 (7)
Definite or probable ST ACS 9 (8) 9 (2) 18(10)
CCS 4 (3) 1 (0) 5 (3)
Total 13 (11) 10 (2) 23 (13)
N is total number of patients (n = within 30 days after randomization).
ACS, acute coronary syndromes; CCS, chronic coronary syndromes; ST, stent
thrombosis; VKA, vitamin K antagonist.
................................................................ ................................................................
....................................................................................................................................................................................................................
Table 2 Type of myocardial infarction by clinical presentation
ACS CCS
Type of MI Groups (N) Type of MI Groups (N)
Edoxaban VKA Total Edoxaban VKA Total
Type 1 11 6 17 Type 1 0 6 6
Type 2 3 3 6 Type 2 2 0 2
Type 3 1 0 1 Type 3 0 0 0
Type 4aa 0 0 0 Type 4aa 0 0 0
Type 4b 4 (4) 4 (0) 8 (4) Type 4b 3 (2) 1 (0) 4 (2)
Type 4c 3 3 6 Type 4c 2 0 2
Total 22 16 38 Total 7 7 14
Type 4b denotes MI associated with stent thrombosis as detected by coronary angiography or autopsy in the setting of myocardial ischaemia in combination with a rise and/or
fall of cardiac biomarkers with at least one value above the 99th percentile URL. Depicted as N = total number (n = number from randomisation to 30 days).
aAnalysed according to the SCAI consensus definition.9



























































































Figure 3 The landmark primary bleeding endpoint analyses up to 14days, and from 15days to 1 year according to clinical presentation (A) acute
coronary syndrome or (B) chronic coronary syndrome, ITT analysis. ACS, acute coronary syndrome; CCS, chronic coronary syndrome; CI, confi-
dence interval; HR, hazard ratio; CRNM, clinically relevant non-major; ITT, intention-to-treat; KM, Kaplan–Meier; VKA, vitamin K antagonist.








































































































































































































































































interactions according to clinical presentation with respect to the pri-
mary bleeding endpoint.
Discussion
In this pre-specified subgroup analysis of the ENTRUST-AF PCI trial,
we analysed safety and efficacy endpoints according to clinical pres-
entation over 12months. For the primary composite endpoint of
ISTHmajor and CRNM bleeding, we did not find a difference in treat-
ment effects between ACS and CCS patients treated with edoxaban
and a P2Y12 inhibitor and VKA in combination with a P2Y12 inhibitor
plus aspirin for 1–12months. Furthermore, there was no evidence
for differences in treatment effects between subgroups in terms of
themain ischaemic endpoint, the net clinical benefit, or each of the in-
dividual components of the composite endpoints in terms of CVD,
MI, stroke, SEE, or definite stent thrombosis. The results of this ana-
lysis among two key patient subgroups are consistent with the main
ENTRUST-AF PCI study outcomes for the primary and main second-
ary outcomes. The numerically higher risk of ISTH major or CRNM
bleeding in the VKA-treated patients compared with edoxaban at
12months was consistent across both subgroups. There was a fa-
vourable HR for VKA relative to edoxaban in the first 2 weeks that
converted to an almost similar HR for both subgroups that continu-
ously favoured edoxaban throughout the remainder of the study
period. The early hazard of bleeding events with edoxaban over VKA
was more pronounced in the CCS patients as compared to the ACS
patients. The lower than expected bleeding rate on VKA in the first 2
weeks may be explained by the high proportion of patients with an
INR <2, no bridging with low molecular weight heparins was used in
VKA patients.4 The time from index PCI to randomization was
shorter in the CCS patients as compared with the ACS patients.
In the ACS group, the numerically lower risk of bleeding with
edoxaban-treated patients compared with VKA-treated patients was
offset by the higher risk of MI without net difference in terms of all is-
chaemic events. However, there was a numerically higher incidence
in all-cause death in ACS patients. The latter may be due to chance
considering that there was no difference in definite or probable stent
thrombosis (Table 1 and Supplementary material online, Table S5) be-
tween the two treatment groups.
In the AUGUSTUS trial, an antithrombotic regimen consisting of
apixaban 5mg twice-daily and a P2Y12 inhibitor without aspirin dem-
onstrated superior safety and similar efficacy in patients with AF who
had ACS, whether managed medically or with PCI, and those under-
going elective PCI compared with regimens that include VKA, aspirin,
or both.10 Oldgren et al.11 reported consistent findings from RE-
DUAL PCI in favour of both dabigatran doses (110 and 150mg
twice-daily) as part of dual-antithrombotic therapy over VKA-based
triple therapy in the pre-specified subgroup analysis of ACS patients
undergoing PCI.
In a meta-analysis of four randomized trials that included 7168 AF
patients after PCI or with ACS12; compared with triple-
antithrombotic therapy with warfarin, dual-antithrombotic therapy
with NOACs was associated with less major bleeding and less major
or CRNM bleeding, and a non-significantly higher composite of death
and ischaemic events but with no difference in mortality. Likewise,
similar findings were observed in a pooled analysis of 10 938 patients
as well as a meta-analysis of four randomized trials encompassing
10 234 AF patients after PCI or with ACS.13,14 The meta-analysis
showed that compared with triple-antithrombotic therapy with war-
farin, dual-antithrombotic therapy with NOACs was associated with
less major bleeding and less major or CRNM bleeding, but increased
risk of stent thrombosis and MI, however, with no difference in all-
cause and cardiovascular mortalities, stroke and major adverse car-
diovascular events.14 Furthermore, pooled data from NOAC trials
(PIONEER AF-PCI, RE-DUAL PCI and AUGUSTUS) suggest that
despite the safety of dual therapy, an initial course of NOAC-based
triple therapy may be desirable in most AF patients.15
Of note, this subgroup analysis of ENTRUST-AF PCI trial points to
a potential benefit of aspirin in the prevention of stent thrombosis
and MI in the specific group of patients with ACS undergoing PCI
who are at high risk for recurrent ischaemic events. We concur with
the AUGUSTUS trial investigators that clinical decision-making is
needed with regards to a 14- to 30-day course of aspirin in patients
with AF receiving an NOAC in combination with a P2Y12-inhibitor
immediately after PCI.10,16,17
In both the ENTRUST-AF PCI and the AUGUSTUS trials, the
approved doses of edoxaban and apixaban, respectively, for the pre-
vention of stroke and SEE in patients with AF, were tested. Dose
adjustments were as per the drug label.
Limitations
The results of this pre-specified subgroup analysis of the ENTRUST-
AF PCI trial need to be considered in view of several limitations.
Although the main study was powered for the primary safety end-
point of ISTH major or CRNM bleeding, the results reported here
separately for both patient subgroups are underpowered. The main
study was not powered for the main efficacy outcome, nor was this
subgroup analysis. All patients received aspirin during hospitalization
for the index procedure. Therefore, the term dual-antithrombotic
therapy refers only to the period after randomization.
Conclusion
An antithrombotic regimen consisting of edoxaban and a P2Y12 in-
hibitor without aspirin provides consistent safety and efficacy in
patients with AF regardless of their clinical presentation throughout
1 year. A trend towards a safety benefit with the edoxaban-based
strategy compared with the VKA-based strategy was noticed in ACS
patients but not in CCS patients. This finding merits further investiga-
tion in a patient-based pooled analysis of the four major trials in the
field, or in a dedicated trial.
Supplementary material
Supplementary material is available at European Heart Journal online.
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